trending Market Intelligence /marketintelligence/en/news-insights/trending/qJzFYsLorlhsQ7qsMeM8pA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Karyopharm blood cancer drug's review period extended by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Karyopharm blood cancer drug's review period extended by US FDA

Karyopharm Therapeutics Inc. said the U.S. Food and Drug Administration has extended the decision date for its new drug application for Selinexor to treat a type of blood cancer by three months.

The agency had granted priority review to the company's application for Selinexor to treat recurring or unresponsive multiple myeloma. Multiple myeloma is an incurable blood cancer that forms in plasma cells, a type of white blood cell responsible for producing antibodies. It is characterized by a recurring pattern of remission and relapse.

In February, the FDA's Oncologic Drugs Advisory Committee recommended that the U.S. regulator wait for results from Boston, a late-stage study evaluating Selinexor in combination with Takeda Pharmaceutical Co. Ltd.'s Velcade in patients with relapsed refractory multiple myeloma, before approving the drug.

Since then, the Newton, Mass.-based biotechnology company has submitted, on the FDA's request, additional clinical information. The agency has moved the Prescription Drug User Fee Act action date from April 6 to July 6.

The European Medicines Agency's Committee for Medicinal Products for Human Use granted accelerated assessment to Selinexor in January, which could reduce the review time of the marketing authorization application to 150 days from the standard 210 days.

Karyopharm's stock rose 7.05% to close at $4.71 on March 15.